Christophe Bourdon, LEO Pharma CEO, on Dermatology Innovation, Rare Disease & Scalable Growth

What It Covers

Christophe Bourdon, CEO of LEO Pharma, outlines how the 60-year dermatology company is scaling toward $2B revenue through first-in-class biologics, rare skin disease expansion, China licensing deals, and AI-driven patient identification.

Key Questions Answered

• •Pipeline expansion strategy: Rather than acquiring new assets immediately, LEO Pharma maximizes existing drugs by running parallel trials across adjacent rare diseases. Dalgoetinib is being tested in PPP, and Spevigo in PG, broadening each asset's commercial footprint without starting from scratch.
• •Innovation filter for BD: Christophe Bourdon applies a strict acquisition criterion: assets must demonstrably change standard of care, not replicate existing options. Me-too products fail on four fronts simultaneously — regulators deprioritize them, providers ignore them, patients gain nothing, and payers refuse reimbursement.
• •China sourcing as a BD priority: LEO Pharma has strengthened scouting capabilities in China and already licensed a PD-1 from Yunxi, now commercialized in Europe for nasopharyngeal cancer. Bourdon views China's innovation pipeline as a primary sourcing channel requiring dedicated, AI-assisted monitoring infrastructure.
• •AI for rare disease patient identification: Fragmented medical records make rare disease patients nearly invisible. LEO Pharma uses AI to scan electronic health records retroactively, identify misdiagnosed or undertreated patients, and direct field teams toward the right hospital systems and prescribers proactively.